@article {179,
	title = {Retigabine (Ezogabine) for Management of Partial onset Seizures: A Mini Review},
	journal = {International Journal of Pharmacology and Clinical Sciences},
	volume = {1},
	year = {2012},
	month = {Sep 2012},
	pages = {85-90},
	type = {New Drug Information},
	chapter = {85},
	abstract = {<p class="rtejustify">Epilepsy, a neurological disorder is currently the target of many drug research companies who are constantly involved in the development of new therapies with novel mechanism of actions as the current plethora of anti epileptics have not been successful in achieving full control of the seizures. Retigabine (Ezogabine) is a new paradigm in the treatment of epilepsy, as it is first of its kind of a drug that targets neuronal voltage gated potassium channels (Kv7) and facili-tates them, thus decreasing the repetitive firing of neurons. It has been approved by European Medicine Agency and USA Food and Drug Administration as an add on therapy for use in patients 18 years and above suffering from partial onset seizures with or without secondary generalization.</p>
},
	keywords = {Ezogabine, Kv7 Channels, Partial onset Seizures, Retigabine},
	author = {Deepika Tikoo and Meenakshi Gupta}
}
